Exelixis (EXEL) News Today $44.16 -1.99 (-4.31%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$44.26 +0.11 (+0.24%) As of 07/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXEL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade)4 hours ago | seekingalpha.comExelixis Target of Unusually Large Options Trading (NASDAQ:EXEL)4 hours ago | americanbankingnews.comStock Traders Buy High Volume of Call Options on Exelixis (NASDAQ:EXEL)July 7 at 11:00 AM | marketbeat.comEULAV Asset Management Raises Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)July 7 at 8:07 AM | marketbeat.comWhat is Zacks Research's Estimate for Exelixis Q4 Earnings?July 6 at 2:49 AM | americanbankingnews.comExelixis, Inc. (NASDAQ:EXEL) Shares Acquired by KBC Group NVJuly 5 at 4:11 AM | marketbeat.comSumitomo Mitsui Trust Group Inc. Buys New Shares in Exelixis, Inc. (NASDAQ:EXEL)July 5 at 4:10 AM | marketbeat.comPeering Into Exelixis's Recent Short InterestJuly 4, 2025 | benzinga.com2 Stocks to Buy With Less Than $50July 4, 2025 | fool.comResearch Analysts Set Expectations for Exelixis Q4 EarningsJuly 4, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Sold by New York State Teachers Retirement SystemJuly 4, 2025 | marketbeat.comZacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and ImmunocoreJuly 3, 2025 | finance.yahoo.comExelixis (NASDAQ:EXEL) Trading 6.4% Higher - Should You Buy?July 3, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Sold by Meritage Portfolio ManagementJuly 3, 2025 | marketbeat.comWhat is Zacks Research's Estimate for Exelixis Q1 Earnings?July 3, 2025 | marketbeat.comAmalgamated Bank Sells 8,226 Shares of Exelixis, Inc. (NASDAQ:EXEL)July 3, 2025 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockJuly 2, 2025 | americanbankingnews.comAsset Management One Co. Ltd. Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)July 1, 2025 | marketbeat.comHC Wainwright Increases Exelixis (NASDAQ:EXEL) Price Target to $53.00June 30, 2025 | marketbeat.comExelixis’s Promising STELLAR-303 Trial Results Lead to Buy Rating and Increased Approval ProbabilityJune 30, 2025 | tipranks.comMonument Capital Management Acquires New Position in Exelixis, Inc. (NASDAQ:EXEL)June 30, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Grows Stake in Exelixis, Inc. (NASDAQ:EXEL)June 30, 2025 | marketbeat.comCambridge Investment Research Advisors Inc. Grows Position in Exelixis, Inc. (NASDAQ:EXEL)June 30, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by BrokeragesJune 29, 2025 | marketbeat.com3 No-Brainer Stocks to Buy for Under $100 Right NowJune 28, 2025 | fool.comNuScale, Hims & Hers, Snowflake, Advance Auto Parts, Exelixis: Trending by AnalystsJune 28, 2025 | tipranks.comRobeco Institutional Asset Management B.V. Buys 100,240 Shares of Exelixis, Inc. (NASDAQ:EXEL)June 28, 2025 | marketbeat.comFlagship Harbor Advisors LLC Takes Position in Exelixis, Inc. (NASDAQ:EXEL)June 27, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL)June 27, 2025 | marketbeat.comExelixis (NasdaqGS:EXEL) Reports Positive Phase 3 Trial Results For Colorectal CancerJune 26, 2025 | finance.yahoo.comStephens Upgrades Exelixis (EXEL) Stock, Raises PTJune 26, 2025 | insidermonkey.comLecap Asset Management Ltd. Has $703,000 Stock Position in Exelixis, Inc. (NASDAQ:EXEL)June 26, 2025 | marketbeat.comStrategic Investment Advisors MI Buys New Stake in Exelixis, Inc. (NASDAQ:EXEL)June 26, 2025 | marketbeat.comMoran Wealth Management LLC Purchases 65,186 Shares of Exelixis, Inc. (NASDAQ:EXEL)June 26, 2025 | marketbeat.comStephens & Co. Upgrades Exelixis (EXEL)June 25, 2025 | msn.comExelixis (NASDAQ:EXEL) Rating Increased to Overweight at StephensJune 24, 2025 | marketbeat.comExelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic ...June 24, 2025 | businesswire.comExelixis (NASDAQ:EXEL) Hits New 1-Year High After Analyst UpgradeJune 24, 2025 | marketbeat.comExelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib TreatmentJune 23, 2025 | seekingalpha.comExelixis (NASDAQ:EXEL) Given Buy Rating at Truist FinancialJune 23, 2025 | marketbeat.comPremarket movers: Tesla, Northern Trust, ExelixisJune 23, 2025 | marketwatch.comExelixis stock soars after cancer drug shows survival benefit in trialJune 23, 2025 | investing.comExelixis Shares Rise Following Positive Results from Cancer-Treatment StudyJune 23, 2025 | marketwatch.com7EXEL : What 9 Analyst Ratings Have To Say About...June 23, 2025 | benzinga.comExelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer DrugJune 23, 2025 | msn.comExelixis Targets $5 Billion In Sales With Promising Data In Key Colorectal Cancer Drug Trial, Stock SoarsJune 23, 2025 | benzinga.comExelixis (NASDAQ:EXEL) Shares Gap Up on Analyst UpgradeJune 23, 2025 | marketbeat.comExelixis (NASDAQ:EXEL) Price Target Raised to $50.00June 23, 2025 | marketbeat.comSawgrass Asset Management LLC Makes New $8.19 Million Investment in Exelixis, Inc. (NASDAQ:EXEL)June 23, 2025 | marketbeat.comExelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved ...June 22, 2025 | gurufocus.com Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address EXEL Media Mentions By Week EXEL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXEL News Sentiment▼1.110.57▲Average Medical News Sentiment EXEL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXEL Articles This Week▼2315▲EXEL Articles Average Week Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Biogen News Incyte News United Therapeutics News Neurocrine Biosciences News BioMarin Pharmaceutical News Exact Sciences News Repligen News Madrigal Pharmaceuticals News Halozyme Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXEL) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.